IRON - Disc Medicine Inc Company Long-Term Liabilities

Public company logo of Disc Medicine Inc (IRON)

Disc Medicine, Inc. (IRON) is developing blood treatments through scientific alliances and joint programs with laboratories. The company's long-term debt metric reflects liability dynamics, with the current level standing at 0.06. Proprietary platforms create a closed-loop therapy cycle for patients, while streamlined drug delivery chains eliminate logistics disruptions in clinical trials.

discmedicine.com (IRON) Company Long-Term Debt: for the period 04/28/2023 - 10/31/2026

Disc Medicine Corp (IRON) - metric breakdowns and financial figures

- share price and expert price forecast:
Share Price discmedicine.com|IRON - Analyst Consensus Forecast
- market capitalization statistics:
Market Valuation Disc Medicine|IRON - Enterprise Value
- shareholders' equity book value data:
Net Asset Value per Share Disc Medicine|IRON - Company Book Value|Market Value to Book Value discmedicine.com|IRON - Cumulative Company Assets
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Disc Medicine, Inc.|IRON - Long-Term Debt to Capital|Short-Term Debt to Equity Disc Medicine Pharma|IRON - Company Debts|Debt to Book Capitalization Ratio Disc Medicine|IRON - Company Long-Term Debt|Short-Term Debt Disc Medicine|Immediate Liquidity discmedicine.com
- earnings and market multiples details:
IRON - Net Profit
Analysis of all company metrics:discmedicine.com (IRON)
Brand item of Disc Medicine Pharma

Long-term debts determine the credit stability of an issuer, recording the total volume of obligations with a maturity of more than one year to assess default risks. By analyzing the long-term debt time series of Disc Medicine, Inc. (IRON), an investor can evaluate the company's margin of safety in the face of geopolitical disruptions in biocomponent logistics, which could slow drug production and necessitate additional debt financing.

Competitors of Disc Medicine, Inc. (IRON)

TGTX: Company Long-Term Indebtedness|Arcellx, Inc. - Company Long-Term Debts|Syndax Pharmaceuticals Inc (SNDX) - Company Long-Term Liabilities|KURA: Company Long-Term Debts|Long-Term Debt ADC Pharma (ADCT)|Company Long-Term Debt Foghorn Therapeutics, Inc.|VOR: Company Long-Term Loans and Borrowings|Company Long-Term Liabilities NKTX (Nkarta, Inc.)|COEP (coeptistx.com) - Company Long-Term Loans and Borrowings|Company Long-Term Debts ATNM (Actinium Pharmaceuticals Inc)|Estrella Immunopharma Corp - Company Long-Term Debt|CASI - Company Long-Term Debt|MRKR: Company Long-Term Debt|IN8bio (INAB) - Company Long-Term Debt|Long-Term Debt Eterna Therapeutics Inc. (ERNA)|Company Long-Term Debt GT Biopharma Corp|Long-Term Debt Aptose APTO|Company Long-Term Debts BPTH|meipharma.com - Company Long-Term Indebtedness|Company Long-Term Debts VINC (Vincerx Pharma)